Biofidelity Secures €22M in Funding: A Game-Changer in Genomic Technology
April 6, 2024, 3:35 am
Location: United Kingdom, England, Cambridge
Employees: 11-50
Founded date: 2019
Total raised: $59M
Cambridge-based Biofidelity, a genomic technology company, has just locked in a hefty €22M in funding, propelling its total funding to a staggering €55.3M. This cash injection, led by key investors like Octopus Ventures and Agilent Technologies, is set to fuel Biofidelity's mission to revolutionize precision medicine.
Biofidelity's flagship product, ASPYRE-Lung, is a game-changer in the world of cancer treatment. This innovative test simplifies and speeds up the detection of biomarkers for non-small cell lung cancer (NSCLC), allowing clinicians to tailor treatment plans for patients in a matter of days, not weeks. And the best part? It's a fraction of the cost of traditional sequencing tests.
Dr. Barnaby Balmforth, Biofidelity's Co-Founder and CEO, is thrilled about the new funding. He sees it as a vote of confidence in Biofidelity's cutting-edge technologies and its mission to democratize precision medicine. With this fresh capital, Biofidelity plans to expand its commercial and clinical presence in the United States, making ASPYRE-Lung more accessible to patients and healthcare providers.
But Biofidelity isn't stopping there. The company is gearing up to establish a dedicated manufacturing facility in the UK and ramp up efforts to broaden its product pipeline. This means more groundbreaking technologies on the horizon, all aimed at improving patient outcomes and advancing the field of genomics.
Since its inception in 2019, Biofidelity has been on a mission to bring the benefits of precision medicine to patients worldwide. With ASPYRE-Lung leading the charge, Biofidelity is poised to disrupt the status quo in genomic testing and research. And with a growing team of top-tier talent and strategic partnerships, the future looks bright for this trailblazing company.
In a world where every moment counts in the fight against cancer, Biofidelity's innovative technologies are a beacon of hope. With this latest funding round, Biofidelity is well-positioned to make a lasting impact on the lives of patients and the future of precision medicine. Watch out world, Biofidelity is here to change the game.
Biofidelity's flagship product, ASPYRE-Lung, is a game-changer in the world of cancer treatment. This innovative test simplifies and speeds up the detection of biomarkers for non-small cell lung cancer (NSCLC), allowing clinicians to tailor treatment plans for patients in a matter of days, not weeks. And the best part? It's a fraction of the cost of traditional sequencing tests.
Dr. Barnaby Balmforth, Biofidelity's Co-Founder and CEO, is thrilled about the new funding. He sees it as a vote of confidence in Biofidelity's cutting-edge technologies and its mission to democratize precision medicine. With this fresh capital, Biofidelity plans to expand its commercial and clinical presence in the United States, making ASPYRE-Lung more accessible to patients and healthcare providers.
But Biofidelity isn't stopping there. The company is gearing up to establish a dedicated manufacturing facility in the UK and ramp up efforts to broaden its product pipeline. This means more groundbreaking technologies on the horizon, all aimed at improving patient outcomes and advancing the field of genomics.
Since its inception in 2019, Biofidelity has been on a mission to bring the benefits of precision medicine to patients worldwide. With ASPYRE-Lung leading the charge, Biofidelity is poised to disrupt the status quo in genomic testing and research. And with a growing team of top-tier talent and strategic partnerships, the future looks bright for this trailblazing company.
In a world where every moment counts in the fight against cancer, Biofidelity's innovative technologies are a beacon of hope. With this latest funding round, Biofidelity is well-positioned to make a lasting impact on the lives of patients and the future of precision medicine. Watch out world, Biofidelity is here to change the game.